Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.

Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors

The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature.

The reported mortality of this type of simultaneous resection remains very high, especially when a cephalic duodenopancreatectomy is associated with a hepatic resection (up to 40%). The benefit in terms of survival remains to be evaluated. The ReSiPaTNE study proposes to create a retrospective cohort of simultaneous pancreatic and hepatic resections for metastatic neuroendocrine tumors in order to evaluate the short and long term results of this type of resection. The evaluation of the results of this type of resection may be useful for the selection of patients for treatment.

Inclusion criteria:

• Major subjects (≥18 years old)
• Subject having had a first pancreatic resection for NET with resections of synchronous metastases
• Subject having had a first pancreatic resection for NET followed by a delayed resection of synchronous metastases
• Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research

Exclusion criteria:

• Subject who expressed their opposition to participating in the study
• Pregnant women
• Subject under safeguard of justice
• Subjects under guardianship or curatorship